Related Experiment Video
Updated: Jan 1, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Kallikrein-kinin system and oxidative stress in cisplatin-induced ovarian toxicity
Laura Silveira Ayres1, Markus Berger2, Isabel Cirne Lima de Oliveira Durli1
1Laboratório de Embriologia e Diferenciação Celular, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos, 2350, Santa Cecília, 90035-903, Porto Alegre, RS, Brazil; Programa de Pós-Graduação em Ciências da Saúde: Ginecologia e Obstetrícia, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos, 2400, 90035003, Porto Alegre, RS, Brazil.
Abstract:
Kallikrein-kinin system (KKS) is involved in vascular reactivity and inflammatory response to cytotoxic drugs. Since cisplatin is a widely used chemotherapy and its cytotoxic mechanism can trigger inflammation and oxidative damage, in this work we evaluated the role of KKS in an animal model of cisplatin-induced ovarian toxicity. Biomarkers of ovarian stem cells, activity of KKS, inflammation and oxidative damage were measured in ovarian tissue of C57BL/6 female mice treated with vehicle or cisplatin (2.5 mg/kg). Cisplatin group presented greater number of atretic follicles, and lower numbers of antral and total viable follicles. Ki67, DDX4 and OCT-4 markers were similar between groups. Cisplatin triggered plasma and ovarian tissue kallikrein generation; and increased expression of bradykinin receptors B1 and B2. Neutrophil and macrophage infiltration markers increased. Superoxide anion generation also increased, while reduced glutathione levels decreased. These results suggest that KKS is activated and contributes to ovarian injury during cisplatin treatment.
Related Concept Videos
Oogenesis
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

